Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(1.06) per share which missed the analyst

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 2

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASD

NEW YORK, June 23, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Asso

Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi

US stocks lower, Nasdaq falls 500 points. Dow down 0.04%, Nasdaq 1.91%, S&P 500 1.27%. Consumer

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge

US stocks down as Dow falls 300 points, while S&P 500 and NASDAQ also decrease. Consumer staples

Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market sessi

Boundless Bio, Inc. (Nasdaq: BOLD) and Serapha Bio, Inc., a privately held biotechnology company dev

Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo

Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.60) per share which beat the analyst co

Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provi

Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (e

Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin deg

TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OT

Boundless Bio offers a highly asymmetric risk/reward profile, trading at a $25M valuation with $107.

Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (e

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncolog

Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status,

Dot's brings its iconic buttery-rich pretzels and bold Original seasoning to Snack Mix! HERSHEY, Pa.

Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.58) per share which missed the analyst

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides

SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncolog

Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism a

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology

BBI-940 novel Kinesin degrader programThe acceptance of the BBI-940 IND enables Boundless to advance

BBI-940 IND accepted; initiation of first-in-human clinical trial on track  for the first half of 20

It's Not About the Water, It's About the Drip. bubba®'s New Look, Fashion-forward Finishes, And Bold

Approved by Archax 12/01/2026 Don't invest unless you're prepared to lose all the money you invest.

Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.62) per share which missed the analyst

Boundless Bio, (NASDAQ:BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (e

Stocks That Hit 52-Week Highs On Friday

The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shoppi

Stocks That Hit 52-Week Highs On Wednesday

Stocks That Hit 52-Week Highs On Tuesday

Stocks That Hit 52-Week Highs On Wednesday

Stocks That Hit 52-Week Highs On Tuesday

Benzinga's Top Upgrades, Downgrades For October 3, 2019

75 Biggest Movers From Yesterday

Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 7, 2018

88 Biggest Movers From Yesterday

70 Stocks Moving In Wednesday's Mid-Day Session